Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Literature
Read More
Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay
Literature
Read More
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
Press Release
Read More
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
Press Release
Read More
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting
Press Release
Read More
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
Press Release
Read More